Keyword Analysis & Research: chimeric antigen receptor
Keyword Research: People who searched chimeric antigen receptor also searched
Search Results related to chimeric antigen receptor on Search Engine
-
Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK537294/
Oct 3, 2022 · Introduction. Chimeric antigen receptors (CARs) are recombinant receptors for antigens which redirect the specificity and function of T lymphocytes and/or other immune cells in a single molecule. The concept of using CARs in cancer immunotherapy is that CARs, which are programmed targeting tumor-associated antigens, can be replicated rapidly ...
DA: 34 PA: 83 MOZ Rank: 44
-
An introduction to chimeric antigen receptor (CAR) T-cell ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/30680780/
Abstract. Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
DA: 98 PA: 55 MOZ Rank: 81
-
CAR T cell - Wikipedia
https://en.wikipedia.org/wiki/CAR_T_cell
In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen.
DA: 91 PA: 22 MOZ Rank: 81
-
The basic principles of chimeric antigen receptor (CAR) design
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667586/
Chimeric antigen receptors (CARs) are a new class of drugs with great potential for cancer immunotherapy. Upon their expression in T lymphocytes, CARs direct potent, targeted immune responses that have recently shown encouraging clinical outcomes in a subset of patients with B cell malignancies.
DA: 10 PA: 40 MOZ Rank: 34
-
Recent advances and discoveries in the mechanisms and ... - Nature
https://www.nature.com/articles/s41568-020-00323-z
Jan 22, 2021 · Abstract. This Review discusses the major advances and changes made over the past 3 years to our understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the field...
DA: 22 PA: 86 MOZ Rank: 79
-
Chimeric Antigen Receptor Therapy | NEJM
https://www.nejm.org/doi/full/10.1056/NEJMra1706169
Jul 5, 2018 · Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion. After infusion, CAR T cells leave the blood and travel to sites of tumor,...
DA: 5 PA: 27 MOZ Rank: 45
-
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
Mar 10, 2022 · They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells.
DA: 41 PA: 65 MOZ Rank: 50
-
Chimeric antigen receptor (CAR) immunotherapy: basic principles
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580929/
Sep 23, 2021 · Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology - PMC. Learn More. User Guide. Journal List. Springer Open Choice. PMC8580929. As a library, NLM provides access to scientific literature.
DA: 94 PA: 97 MOZ Rank: 80
-
Chimeric Antigen Receptor - an overview | ScienceDirect Topics
https://www.sciencedirect.com/topics/immunology-and-microbiology/chimeric-antigen-receptor
Chimeric antigen receptors are formed by fusing a tumor-specific antibody single-chain variable fragment (scFvs) via a transmembrane linker domain to the CD3ζ chain of the T cell receptor. This fusion construct is then transfected into autologous cytolytic lymphocytes.
DA: 79 PA: 56 MOZ Rank: 44
-
CAR immune cells: design principles, resistance and the next
https://www.nature.com/articles/s41586-023-05707-3
Feb 22, 2023 · The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and plasma cell malignancies has validated the use of this therapeutic class for liquid cancers, but...
DA: 90 PA: 1 MOZ Rank: 39